Pheton Holdings Limited (PTHL): Price-to-Sales Ratio

Brandmark of Pheton Holdings Ltd (PTHL)

Pheton Holdings Ltd (PTHL) is implementing specialized brachytherapy software through partnerships with Chinese clinics. The niche focus of the business is offset by strong patent protection, while its technological base in Asia facilitates the development of innovative IT solutions. The GURU.Markets platform presents this normalized P/S ratio for the company, where 27.50 determines the current value of the metric, allowing for an assessment of the asset's market value relative to its revenue.

PTHL: Pheton Holdings Ltd P/S Multiple 09/06/2024 - 01/16/2026

Metric breakdowns and analytics for Pheton Holdings Ltd (PTHL)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company analysis:ftzy.com.cn (PTHL)
Brand item of Pheton

The P/S ratio determines the market value of one dollar of revenue by dividing the business capitalization by annual sales volume. This metric allows an investor to assess the degree of asset overheating and the risk of capital freeze during periods of structural transformation. By analyzing the dynamics of the capitalization-to-revenue ratio, one can observe the impact of regulatory barriers in China and high R&D costs. These factors constrain the profitability of Pheton Holdings Ltd. (PTHL), creating pressure on its fundamental valuation.

Who Pheton Holdings Ltd competes with

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Revenue Ratio|SCPH (scpharmaceuticals.com) - P/S Multiple|TECX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Market Capitalization-to-Revenue Ratio|P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Market Capitalization-to-Revenue Ratio BHST|Invizyne Technologies - P/S Multiple|oramed.com (ORMP) - Market Cap to Revenue|ENTX (enterabio.com) - Market Cap to Revenue|Market Cap to Revenue Ratio HYFT|ABVC (ABVC BioPharma, Inc) - P/S Multiple|P/S Multiple cumberlandpharma.com|Price-to-Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Price-to-Revenue Multiple|P/S Multiple TELO (telomirpharma.com)|RANI - Market Cap to Revenue|SNYR - Price-to-Revenue Ratio|rallybio.com - Market Cap to Sales Volume|LEXX: P/S Multiple|Market Cap to Revenue Pulmatrix Inc|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)